Time to engraftment, transfusion requirements, GVHD
| . | BMT . | PBSCT . | CD34+PBSCT . | P CD34-PBSCT versus BMT/ CD34-PBSCT versus PBSCT . |
|---|---|---|---|---|
| Time to engraftment (d) | ||||
| Neutrophil level higher than 500/μL (median, range) | 18 (14-25) | 13 (9-18) | 8 (7-13) | < .001/< .01 |
| Platelet level higher than 20 000/μL (median, range) | 10 (6-27) | 9 (5-23) | 11 (5-18) | NS/NS |
| Platelet level higher than 50 000/μL (median, range) | 23 (14-100) | 17 (12-30) | 14 (7-25) | < .02/< .05 |
| Transfusions (no. of units) | ||||
| Red cells (median, range) | 8 (4-91) | 10 (2-54) | 10 (4-20) | NS/NS |
| Platelets (median, range) | 9 (1-117) | 11 (3-85) | 13 (3-31) | NS/NS |
| Acute GVHD (grades), no. (%) | ||||
| 0 | 3 (14) | 2 (11) | 24 (75) | < .01/< .01 |
| I | 13 (59) | 7 (37) | 5 (16) | < .01/NS |
| II | 3 (14) | 4 (21) | 2 (6) | NS |
| III | 2 (9) | 1 (5) | 1 (3) | NS |
| IV | 1 (5) | 5 (26) | 0 | NS |
| Chronic GVHD,*no. (%) | ||||
| No chronic GVHD | 11 (50) | 9 (47) | 23 (79) | < .05/< .01 |
| Limited | 8 (36) | 4 (21) | 4 (14) | NS |
| Extensive | 3 (14) | 6 (32) | 2 (7) | NS |
| . | BMT . | PBSCT . | CD34+PBSCT . | P CD34-PBSCT versus BMT/ CD34-PBSCT versus PBSCT . |
|---|---|---|---|---|
| Time to engraftment (d) | ||||
| Neutrophil level higher than 500/μL (median, range) | 18 (14-25) | 13 (9-18) | 8 (7-13) | < .001/< .01 |
| Platelet level higher than 20 000/μL (median, range) | 10 (6-27) | 9 (5-23) | 11 (5-18) | NS/NS |
| Platelet level higher than 50 000/μL (median, range) | 23 (14-100) | 17 (12-30) | 14 (7-25) | < .02/< .05 |
| Transfusions (no. of units) | ||||
| Red cells (median, range) | 8 (4-91) | 10 (2-54) | 10 (4-20) | NS/NS |
| Platelets (median, range) | 9 (1-117) | 11 (3-85) | 13 (3-31) | NS/NS |
| Acute GVHD (grades), no. (%) | ||||
| 0 | 3 (14) | 2 (11) | 24 (75) | < .01/< .01 |
| I | 13 (59) | 7 (37) | 5 (16) | < .01/NS |
| II | 3 (14) | 4 (21) | 2 (6) | NS |
| III | 2 (9) | 1 (5) | 1 (3) | NS |
| IV | 1 (5) | 5 (26) | 0 | NS |
| Chronic GVHD,*no. (%) | ||||
| No chronic GVHD | 11 (50) | 9 (47) | 23 (79) | < .05/< .01 |
| Limited | 8 (36) | 4 (21) | 4 (14) | NS |
| Extensive | 3 (14) | 6 (32) | 2 (7) | NS |
NS indicates not significant.
Number of evaluable patients in the BMT group (n = 22), PBSCT group (n = 19), and CD34+-PBSCT group (n = 29).